Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kangji Medical Holdings Limited ( (HK:9997) ) has issued an announcement.
Kangji Medical Holdings Limited reported an 8.3% increase in revenue for the first half of 2025, reaching RMB496.6 million, driven by higher sales of disposable products. However, the company’s net profit attributable to owners decreased by 7.0% due to reduced other income and gains, and increased losses from its associate, Weijing Medical. The Board did not recommend an interim dividend for this period.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
More about Kangji Medical Holdings Limited
Kangji Medical Holdings Limited is a company incorporated in the Cayman Islands, primarily engaged in the medical industry. It focuses on the production and sale of disposable medical products, with a market emphasis on innovative healthcare solutions.
Average Trading Volume: 6,968,146
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.26B
See more insights into 9997 stock on TipRanks’ Stock Analysis page.